Syros Pharmaceuticals (SYRS)
(Delayed Data from NSDQ)
$6.52 USD
+0.38 (6.19%)
Updated Jul 16, 2024 04:00 PM ET
After-Market: $6.55 +0.03 (0.46%) 7:06 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Price, Consensus and EPS Surprise
SYRS 6.52 +0.38(6.19%)
Will SYRS be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for SYRS based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for SYRS
2seventy bio, Inc. (TSVT) Reports Q1 Loss, Tops Revenue Estimates
Will Femasys Inc. (FEMY) Report Negative Q1 Earnings? What You Should Know
SYRS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Analysts Estimate Syros Pharmaceuticals, Inc. (SYRS) to Report a Decline in Earnings: What to Look Out for
Alkermes (ALKS) Q1 Earnings and Revenues Miss Estimates
The Zacks Analyst Blog Highlights Bristol Myers, Moderna, 2seventy bio, Amylyx Pharmaceuticals and Syros Pharmaceuticals
Other News for SYRS
TD Cowen Keeps Their Buy Rating on Syros Pharmaceuticals (SYRS)
Buy Rating Affirmed: Syros Pharmaceuticals’ Promising Tamibarotene for MDS Treatment
JMP Securities Reaffirms Their Buy Rating on Syros Pharmaceuticals (SYRS)
Syros to Host Webcast Event on Higher-Risk Myelodysplastic Syndrome and the Opportunity for Tamibarotene to Become the New Frontline Standard-of-Care for Patients with RARA Gene Overexpression
Syros Pharmaceuticals’ Shareholders Approve Key Updates and Elections